Minimal requirements for antiphospholipid antibodies ELISAs proposed by the European Forum on antiphospholipidantibodies

被引:118
作者
Tincani, A
Allegri, F
Balestrieri, G
Reber, GD
Sanmarco, M
Meroni, P
Boffa, MC
机构
[1] Osped Civile, I-25125 Brescia, Italy
[2] Univ Hosp Geneva, Geneva, Switzerland
[3] Hop Conception, Marseille, France
[4] Univ Milan, Ist Auxol, I-20122 Milan, Italy
[5] Hop Pitie, Dept Int Med, F-75651 Paris, France
关键词
antiphospholipid antibodies immunoassays; anticardiolipin; anti-beta2; glycoprotein; 1; standardization; cut-off; antiphospholipid antibodies syndrome;
D O I
10.1016/j.thromres.2004.06.035
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Antiphospholipid ELISAs are part of the Antiphospholipid Antibodies Syndrome classification criteria, having the same diagnostic value as lupus anticoagulant. However, sometimes their results appear scarcely meaningful especially when wide metanalyses studies are performed, probably because of their well-known inter-laboratory variability. The application of a common protocol was shown to improve the test reproducibility, but this observation did not have any influence on the routine performances. After discussion among experts at the European level, we identified four conditions named "minimal requirements" considered useful to decrease the inter-laboratory variability: (1) to run the samples in duplicate; (2) to determine the cut off level in each laboratory analysing at least 50 samples from normal subjects, possibly age- and sex-matched with the patient population usually attending the Centre; (3) to calculate the cut-off level in percentiles; (4) to use stable external controls in the test. A collaborative study involving 36 European centres proved that the use of monoclonal anti-beta2 gLycoprotein I antibodies, HCAL (IgG) and EY2C9 (IgM) as standards, can help to reduce the inter-laboratory coefficient of variation both in anticardiolipin (aCL) and anti-beta 2GPI (anti-beta2 glycoprotein I) ELISA. Therefore, we propose HCAL and EY2C9 as external controls, but other monoclonal or polyclonal preparations may be considered. During an interactive workshop held last May in Italy, 16 companies producing these tests agreed to consider the introduction of the "requirements" in their products. We suggest to adopt these "requirements" particularly in clinical studies, in order to compare more easily the Literature data. (c) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:553 / 558
页数:6
相关论文
共 17 条
[1]   Recent advances in antiphospholipid antibodies and antiphospholipid syndromes in pediatric populations [J].
Avcin, T ;
Cimaz, R ;
Meroni, PL .
LUPUS, 2002, 11 (01) :4-10
[2]   Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature [J].
Galli, M ;
Luciani, D ;
Bertolini, G ;
Barbui, T .
BLOOD, 2003, 101 (05) :1827-1832
[3]   Anti-β2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome [J].
Galli, M ;
Luciani, D ;
Bertolini, G ;
Barbui, T .
BLOOD, 2003, 102 (08) :2717-2723
[4]   Revisiting the anticardiolipin test and its standardization [J].
Harris, EN ;
Pierangeli, SS .
LUPUS, 2002, 11 (05) :269-275
[5]  
HARRIS EN, 1986, CLIN EXP IMMUNOL, V68, P215
[6]  
Ichikawa K, 1999, ARTHRITIS RHEUM, V42, P2461, DOI 10.1002/1529-0131(199911)42:11<2461::AID-ANR25>3.0.CO
[7]  
2-O
[8]   BETA(2)-GLYCOPROTEIN-I REACTIVITY OF MONOCLONAL ANTICARDIOLIPIN ANTIBODIES FROM PATIENTS WITH THE ANTIPHOSPHOLIPID-SYNDROME [J].
ICHIKAWA, K ;
KHAMASHTA, MA ;
KOIKE, T ;
MATSUURA, E ;
HUGHES, GRV .
ARTHRITIS AND RHEUMATISM, 1994, 37 (10) :1453-1461
[9]  
Pierangeli SS, 1998, J RHEUMATOL, V25, P156
[10]   Antiphospholipid syndrome in the elderly: Caution [J].
Piette, JC ;
Cacoub, P .
CIRCULATION, 1998, 97 (22) :2195-2196